Advertisement

PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 12–12 | Cite as

Cost effectiveness and budget impact of tisagenlecleucel

Meeting report
  • 3 Downloads

References

  1. 1.
    Yang H, et al. Cost-Effectiveness of Tisagenlecleucel for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma : a Canadian Societal Perspective. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN177, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85193?pdfid=58705
  2. 2.
    Yang H, et al. Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: a Canadian Societal Perspective. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN170, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/86304?pdfid=58627
  3. 3.
    Hollmann S, et al. Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN72, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85168?pdfid=58708
  4. 4.
    Hollmann S, et al. Budget Impact Analysis of Tisagenlecleucel for the Treatment of Paediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in England. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN68, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85189?pdfid=58707

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations